The Advanced Biomaterials Translation Laboratory develops novel peptide-based hydrogels that are injected and then self-reassemble in situ in tissue spaces. These constructs can be designed to deliver drugs and other small cargo over day, week or month-long periods. Facile modification of the base peptide allows for the development of novel drugs that can specifically target angiogenesis, neurogenesis, osteogenesis and even the delivery of antigenic sequences for vaccine development. Motivated by translational goals, the lab engages in academic science, biopharmaceutical development, medical device prototyping, drug design and delivery and entrepreneurship. Our current work has led to the establishment of platforms for the treatment of maladaptive angiogenesis, ischemic tissue disease, diabetic ulcer wound healing and dental pulp regeneration, among other therapies.